# Darolutamide

## Nubeqa F.C. 300mg

##### 臨採

| TAH Drug Code      | [ONUB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ONUB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treating patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Used in combination with docetaxel for treating metastatic hormone-sensitive prostate cancer (mCSPC, also known as mHSPC).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | Prostate cancer, Nonmetastatic, castration resistant: 600mg (two 300mg tablets) PO BID with food until disease progression or unacceptable toxicity. Adverse reactions (Grade 3 or greater toxicity or intolerable events): Withhold dosing or reduce to 300mg BID until symptoms improve; then resume at a dose of 600mg BID; dosage reduction below 300mg BID is not recommended Hormone sensitive prostate cancer, Metastatic, in combination with docetaxel: 600mg (two 300mg tablets) PO BID with food in combination with docetaxel 75mg/m(2) IV on day 1 and every 21 days for 6 cycles (start within 6 weeks of darolutamide)e; continue until disease progression or unacceptable toxicity even if a cycle of docetaxel is delayed, interrupted, or discontinued. Give a gonadotropin-releasing hormone (GnRH) analog concurrently in patients without a bilateral orchiectomy. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to darolutamide or any component of the formulation. Women and children.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Common: Rash (3%), Pain in limb (6%), Fatigue (16%) >10%: Decreased neutrophils (20%; grades 3/4: 4%), Increased serum aspartate aminotransferase (23%), increased serum bilirubin (16%), Asthenia (16%), fatigue (16%) 1-10%: Heart failure (2%), ischemic heart disease (4%), Skin rash (4%), Limb pain (6%) Frequency not defined: Hypertension, Diarrhea, nausea, Hematuria, urinary retention, Pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/darolutamide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

